Mosquito borne diseases such as malaria, dengue, chikungunya virus, yellow fever, West Nile virus, zika virus continue to spread rapidly across tropical and subtropical regions worldwide. According to WHO, over 3.9 billion people in over 128 countries are at risk of contracting malaria and an estimated 214 million cases of malaria occurred globally in 2015 and 438,000 people died of malaria. Dengue virus causes illness in about 100 million people each year in over 100 endemic countries and puts over 3.9 billion people at risk of contracting the disease.

The global Mosquito Borne Disease Control Market is estimated to be valued at Us$ 3.11 Bn in 2023 and is expected to exhibit a CAGR Of 6.5% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Mosquito borne diseases severely impact public health & economic development. To curb the rapid spread of these diseases, there is an increasing demand for effective control measures including insect repellents, mosquito coils and vaporizers, sprays, baits, bed nets and clothing, preventive drugs, and vaccines. Growing awareness regarding personal protection measures and government initiatives to eradicate these diseases are driving the need for mosquito borne disease control solutions. The global mosquito borne disease control market offers lucrative opportunities for players as the demand for integrated solutions for prevention of diseases like malaria, dengue, zika, etc. is increasing across communities and households in endemic regions.

Market key trends:

One of the major trends anticipated to bolster the growth of mosquito borne disease control market over the forecast period is rising R&D activities for development of novel vaccines and drugs. For instance, RTS,S/AS01 is the first vaccine approved by European Medicines Agency for prevention of Plasmodium falciparum malaria in children aged 6 weeks to 17 months. Sanofi Pasteur developed this vaccine after 25 years of research.

Growing government investments in technology-driven solutions like drones spraying insecticides, G.I.S mapping of mosquito breeding hotspots and integrated vector control programs are also expected to support market growth. Advanced tools help target interventions more effectively. For example, South Korea has extensively used G.I.S technology to curb malaria between 1946 to 1960s achieving complete eradication.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is moderate. Mosquito borne diseases are very common and the costs associated with R&D of new drugs and therapeutics are very high. However, opportunities exist for new players to introduce innovative treatments and diagnostics.

Bargaining power of buyers: The bargaining power of buyers is moderate to high. Buyers have several treatment options available and government programs provide subsidized access to drugs. This enables buyers to negotiate on price and quality of offerings.

Bargaining power of suppliers: The bargaining power of suppliers is moderate. While requirements and regulations ensure quality supply of active pharmaceutical ingredients, the presence of alternative suppliers limits potential monopoly pricing by any single supplier.

Threat of new substitutes: The threat of new substitutes is low to medium. While alternative treatment approaches are being researched, proven drug therapies and vaccines currently have few substitutes that offer the same efficacy and safety.

Competitive rivalry: The competitive rivalry is high due to presence of many global and regional players. Companies compete on factors like pricing, R&D of innovative products, and marketing. Partnerships and acquisitions are common in the industry.

Key Takeaways

The Global Mosquito Borne Disease Market Demand is expected to witness high growth over the forecast period 2023 to 2030. The growing risk of mosquito borne illnesses, rising investment in treatment research and government support are driving the market expansion.

Regional analysis:

The market is expected to be dominated by Asia Pacific region. Factors such as warmer climate, limited access to healthcare in some countries, and increasing healthcare spending are contributing to high disease prevalence and growth opportunities in the region. North America and Europe are also significant markets due to developed healthcare infrastructure and spending.

Key players:

Key players operating in the Mosquito Borne Disease market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc. Companies are engaged in R&D and partnerships to develop novel drugs and combinations to better treat mosquito transmitted diseases.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it